The American Cancer Society will launch two national roundtables—one focused on cervical cancer, the other breast cancer—to bring together leading organizations and experts with the goal of improving health equity and access to cancer screening.
The Cancer Prevention and Research Institute of Texas on Feb. 16 announced 74 new cancer research and prevention grants totaling over $112,768,740.
Fox Chase Cancer Center has been awarded a Research Education Program (R25) grant that will allow the center to expand the reach of its University of Delaware-Fox Chase Cancer Center Summer Research Fellowship.
U.S. Sens. Ben Cardin (D-MD) and Lisa Murkowski (R-AK) introduced the Reducing Hereditary Cancer Act, bipartisan legislation to expand access to medically-appropriate genetic testing to determine an individual’s risk of developing hereditary cancer—and access to evidence-based medical care to reduce risk for those who have a predisposing genetic mutation.
The American Cancer Society’s National Consortium for Cancer Screening and Care announced nine consensus recommendations to accelerate recovery from the pandemic and improve access to cancer screening and care.
A team from the SWOG Cancer Research Network that analyzed data on more than 20,000 patients from more than 200 clinical trials reports found that compared to men, women have a higher risk of severe adverse events from targeted therapy and immunotherapy. Past research has also shown that women tend to have more adverse events from chemotherapy.
A study led by researchers at Yale Cancer Center and the University of Maryland Comprehensive Cancer Center showed that ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone. The data show it also may significantly extend both progression free survival and overall survival.
A study led by Yale Cancer Center researchers showed enfortumab vedotin is effective in patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy.
Interim results from the single center, randomized, phase III MIRAGE trial, a UCLA-led study comparing MRIdian MRI-guided vs. CT-guided stereotactic body radiotherapy (SBRT) for localized prostate cancer, signaled superiority of MRIdian MRI-guided SBRT with a significant reduction in acute grade ≥2 GU toxicity in men receiving MRI-guided SBRT over those receiving CT-guided SBRT.
FDA granted Fast Track designation for IO-202, a first-in-class myeloid checkpoint inhibitor targeting leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with relapsed or refractory acute myeloid leukemia.
